Key result
The novel Genetic Bleeding Risk Score (GBRS) predicted bleeding events in first-time users of oral anticoagulants with a positive predictive value of 83.3% and a specificity of 97.4%.
Why the study?
Does a genetic bleeding risk score (GBRS) improve the prediction of bleeding compared to clinical factors alone in patients on long-term oral anticoagulant therapy?
Cohort (n=310)
No
Does a genetic bleeding risk score (GBRS) improve the prediction of bleeding compared to clinical factors alone in patients on long-term oral anticoagulant therapy?
A novel genetic bleeding risk score incorporating CYP2C9, VKORC1, and F5 variants alongside clinical factors significantly improves bleeding risk prediction in first-time users of oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GBRS in new OAC users; leaves open validation against clinical scores alone.
The present study focussed on deriving and validating a 'genetic bleeding risk score' (GBRS) based on genetic and non-genetic factors associated with bleeding in patients on long term anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Nahar et al. (2013) conducted a cohort in Patients on long-term oral anticoagulant therapy (n=310). Genetic Bleeding Risk Score (GBRS) vs. Low risk score was evaluated on Drug-induced bleeding (minor and major) (AUC 0.757, 95% CI 0.600-0.914). The novel Genetic Bleeding Risk Score (GBRS) predicted bleeding events in first-time users of oral anticoagulants with a positive predictive value of 83.3% and a specificity of 97.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: